Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy

Antibodies against programmed death (PD) pathway are revolutionizing cancer immunotherapy. Currently five antibodies against PD-1/PD-L1 have been approved. The clinical use of these antibodies is rapidly expanding. Incorporation of PD antibodies into chemotherapy regimens is in active clinical inves...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Bingshan, Song, Yongping, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712158/
https://www.ncbi.nlm.nih.gov/pubmed/29195503
http://dx.doi.org/10.1186/s13045-017-0541-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712158/
https://www.ncbi.nlm.nih.gov/pubmed/29195503
http://dx.doi.org/10.1186/s13045-017-0541-9

Ejemplares similares